Aspa Therapeutics

Aspa Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company dedicated to developing treatments for Canavan disease, a devastating genetic disorder with no FDA-approved therapy. Aspa is led by a group of seasoned biotech executives. The company collaborates with patients and physicians with the aim of bringing safe and effective treatments for Canavan disease to patients as soon as possible.